methenolone and Breast-Neoplasms

Topics: Breast Neoplasms; Female; Humans; Menopause; Methenolone; Randomized Controlled Trials as Topic; Survival Rate; Testosterone

The effect of additive administration of methenolone oenanthate (Primobolan) on lipid metabolism was studied in 28 menopausal women with metastasizing carcinoma of the breast. In ten women hyperlipoproteinaemia type IIa was demonstrated in the course of treatment, while in two there was hyperlipoproteinaemia type IIb. One of the latter patients had a myocardial infarction in the course of treatment. There was no relationship between the level of hypercholesterolaemia and the methenolone dosage. Nor was it possible to classify the type of cholesterolaemia as a bile stasis syndrome. The hyperlipoproteinaemia regressed in every case once methenolone treatment was discontinued.

Topics: Bone Neoplasms; Breast Neoplasms; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Methenolone; Middle Aged; Neoplasm Metastasis; Skin Neoplasms

The medical records of 66 women treated with metenolone for metastasized breast carcinomas were analysed. In 26 patients a remission developed with a mean duration of 8.2 (3-29) months. Patients whose treatment started in the first year after the menopause as well as patients with a beneficial effect of a therapeutic ovariectomy in the past were more often improved by metenolone than average. Metenolone had a better effect against osseous metastases than against visceral metastases. In most cases the treatment was well tolerated. In four patients, however, the treatment had to be interrupted because of cholestasis, pulmonary embolism and hypercalcaemia.

Topics: Adult; Aged; Anabolic Agents; Breast Neoplasms; Castration; Female; Humans; Mastectomy; Menopause; Methenolone; Middle Aged

Forty-three patients with disseminated or inoperable carcinoma of the breast were treated with Metenolone Enanthate (Primobolan Depot) with doses of 400 to 1 200 mg/week for at least 3 months. Objective remissions lasting longer than 3 months occurred in 8 out of 41 evaluable patients. Soft tissue metastases responsed best. Liver and brain metastases were unaffected. The therapeutic efficiency of Primobolan Depot is comparable to that of testosterone propionate but the agent is less virilising.

Topics: Aged; Breast Neoplasms; Female; Hirsutism; Hoarseness; Humans; Libido; Lymphatic Metastasis; Methenolone; Middle Aged; Neoplasm Metastasis; Remission, Spontaneous

Topics: Breast Neoplasms; Castration; Climacteric; Cyclophosphamide; Cytoplasm; Electrophoresis; Estradiol; Estrogens; Ethinyl Estradiol; Female; Glucocorticoids; Humans; Hypophysectomy; Menopause; Methenolone; Neoplasm Metastasis; Protein Binding; Pyrrolidines; Receptors, Cell Surface; Tritium

Topics: Breast Neoplasms; Fluorouracil; Humans; Lung Neoplasms; Methenolone; Palliative Care; Radiation Injuries; Radiography; Vitamin B Complex

Topics: Adult; Aged; Breast Neoplasms; Germany, West; Humans; Lymphatic Metastasis; Male; Methenolone; Middle Aged; Prognosis; Testosterone

Topics: Breast Neoplasms; Female; Humans; Methenolone

Topics: Adrenal Cortex Hormones; Anabolic Agents; Androgens; Antineoplastic Agents; Breast Neoplasms; Castration; Estrogens; Geriatrics; Humans; Lactones; Methenolone; Neoplasm Metastasis; Neoplasms; Osteoporosis; Steroids